Riding On Exosome Potential, Evox Eyes Unicorn Status

UK Firm Completes £69.2m Series C Financing

 
• By Kevin Grogan

A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.

A toy train pulling a cargo of money This picture could be a reference to 'money delivery', gravy train, cargo, freight. Also, money supply and transferring money or wiring money.
Oxford's Evox gets cash boost • Source: Archive

Evox Therapeutics Limited CEO Tony de Fougerolles has told Scrip that the UK firm's exosome expertise, strong pipeline and big pharma partnerships can help it become a 'unicorn' billion-dollar biotech.

He was speaking as Evox concluded a series C financing round that raised £69.2m ($95.4m) led by long-time backer Redmile...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business